Literature DB >> 24805828

Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer.

Ling Liu1, Jing Zou, Qi Wang, Fu-Qiang Yin, Wei Zhang, Li Li.   

Abstract

The aim of this study is to examine the microRNA (miRNA) expression of epithelial ovarian cancer (EOC) in both drug-resistant and drug-sensitive tissues and to explore the pathogenic characteristics of drug-resistant miRNAs in EOC. The samples with 10 cases of drug-resistant and drug-sensitive EOC tissue were obtained from undergoing surgical resection of ovarian cancer (OC). Total miRNAs were extracted and isolated, respectively. Hybridization was carried out on miRNA microarray chip. Real-time polymerase chain reaction (RT-PCR) was performed to confirm the difference of miRNA expression. Bioinformatic software was used to predict the possible target genes of each miRNA which expressed differently. The results indicated that four miRNAs related drug-resistance been identified, and the expression of hsa-miR-152 and hsa-miR-381 in drug-resistant OC tissue was significantly higher compared with those in drug-sensitive tissue (P < 0.01). However, expression of hsa-miR-200a-3p and hsa-miR-429 were downregulated in drug-resistant tissues (P < 0.01). The results obtained by miRNA microarrays of differential expression with hsa-miR-106b-3p, hsa-miR-152, hsa-miR-200a-3p, hsa-miR-381, and hsa-miR-429 were confirmed by real-time PCR. There were 62 significantly different miRNAs, including 42 significant upregulated miRNAs and 20 significant downregulated miRNAs in the drug-resistant tissue. Five databases, including Target Scan, miRanda, miRDB, PicTar5, and RNA22, were used for bioinformatics prediction. In conclusion, miRNA microarray analysis has become a fast and efficient molecular biological technology for the study of biological information. hsa-miR-152, hsa-miR-200a-3p, hsa-miR-381, and hsa-miR-429 may participate in the formation of drug resistance in EOC through the target genes predicted.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24805828     DOI: 10.1007/s13277-014-1970-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  19 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel.

Authors:  Mohamed Kamel Hassan; Hidemichi Watari; Lane Christenson; Saverio Bettuzzi; Noriaki Sakuragi
Journal:  Tumour Biol       Date:  2011-07-15

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 4.  MicroRNAs, cancer and cancer stem cells.

Authors:  Amy L Zimmerman; Shiyong Wu
Journal:  Cancer Lett       Date:  2010-10-20       Impact factor: 8.679

5.  Role of microRNAs in drug-resistant ovarian cancer cells.

Authors:  Antonio Sorrentino; Chang-Gong Liu; Antonio Addario; Cesare Peschle; Giovanni Scambia; Cristiano Ferlini
Journal:  Gynecol Oncol       Date:  2008-09-26       Impact factor: 5.482

Review 6.  MicroRNAs in cell proliferation, cell death, and tumorigenesis.

Authors:  H-W Hwang; J T Mendell
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

7.  miR-222 is upregulated in epithelial ovarian cancer and promotes cell proliferation by downregulating P27kip1.

Authors:  Chaoyang Sun; Na Li; Bo Zhou; Zongyuan Yang; Dong Ding; Danhui Weng; Li Meng; Shixuan Wang; Jianfeng Zhou; Ding Ma; Gang Chen
Journal:  Oncol Lett       Date:  2013-06-13       Impact factor: 2.967

8.  Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.

Authors:  Yong-Wan Kim; Eun Young Kim; Doin Jeon; Juinn-Lin Liu; Helena Suhyun Kim; Jin Woo Choi; Woong Shick Ahn
Journal:  Drug Des Devel Ther       Date:  2014-02-24       Impact factor: 4.162

9.  microRNA-106a modulates cisplatin sensitivity by targeting PDCD4 in human ovarian cancer cells.

Authors:  Hao Li; Haiyuan Xu; Huiling Shen; Hao Li
Journal:  Oncol Lett       Date:  2013-10-29       Impact factor: 2.967

10.  Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.

Authors:  Ross M Drayton; Ewa Dudziec; Stefan Peter; Simone Bertz; Arndt Hartmann; Helen E Bryant; James Wf Catto
Journal:  Clin Cancer Res       Date:  2014-02-10       Impact factor: 12.531

View more
  9 in total

1.  MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.

Authors:  Hong-Min Zhao; Wei Wei; Yu-Hui Sun; Jian-Hua Gao; Qi Wang; Jian-Hua Zheng
Journal:  Tumour Biol       Date:  2015-04-07

2.  Expression of microRNA-30a-5p in drug-resistant and drug-sensitive ovarian cancer cell lines.

Authors:  Jin Liu; Xiaohua Wu; Hongmei Liu; Yijuan Liang; Xinping Gao; Zhihui Cai; Weiming Wang; Hui Zhang
Journal:  Oncol Lett       Date:  2016-07-08       Impact factor: 2.967

3.  Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1.

Authors:  Jing Zou; Ling Liu; Qi Wang; Fuqiang Yin; Zhijun Yang; Wei Zhang; Li Li
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

4.  Expression and clinical significance of microRNA-152 in supragalottic laryngeal carcinoma.

Authors:  Yan Song; Yuan Tian; Wei-Liang Bai; Xiu-Lan Ma
Journal:  Tumour Biol       Date:  2014-08-06

5.  Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.

Authors:  Zeyou Wang; Jing Yang; Gang Xu; Wei Wang; Changhong Liu; Honghui Yang; Zhibin Yu; Qianqian Lei; Lan Xiao; Jing Xiong; Liang Zeng; Juanjuan Xiang; Jian Ma; Guiyuan Li; Minghua Wu
Journal:  Oncotarget       Date:  2015-02-20

6.  Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease.

Authors:  Jarkko Soronen; Hannele Yki-Järvinen; You Zhou; Sanja Sädevirta; Antti-Pekka Sarin; Marja Leivonen; Ksenia Sevastianova; Julia Perttilä; Pirkka-Pekka Laurila; Alexander Sigruener; Gerd Schmitz; Vesa M Olkkonen
Journal:  Physiol Rep       Date:  2016-01

Review 7.  MicroRNA: a new and promising potential biomarker for diagnosis and prognosis of ovarian cancer.

Authors:  Manish K Pal; Shyam P Jaiswar; Vinaya N Dwivedi; Amit K Tripathi; Ashish Dwivedi; Pushplata Sankhwar
Journal:  Cancer Biol Med       Date:  2015-12       Impact factor: 4.248

8.  MiR-17-5p regulates cell proliferation and migration by targeting transforming growth factor-β receptor 2 in gastric cancer.

Authors:  Yanjun Qu; Haiyang Zhang; Jingjing Duan; Rui Liu; Ting Deng; Ming Bai; Dingzhi Huang; Hongli Li; Tao Ning; Le Zhang; Xia Wang; Shaohua Ge; Likun Zhou; Benfu Zhong; Guoguang Ying; Yi Ba
Journal:  Oncotarget       Date:  2016-05-31

9.  Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma.

Authors:  Yunchao Li; Chunhua Zhao; Zhibin Yu; Jiarui Chen; Xiaoling She; Peiyao Li; Changhong Liu; Yan Zhang; Jianbo Feng; Haijuan Fu; Bing Wang; Lei Kuang; Lei Li; Guohua Lv; Minghua Wu
Journal:  Oncotarget       Date:  2016-10-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.